Literature DB >> 24341521

Case of presymptomatic aceruloplasminemia treated with deferasirox.

Mayumi Tai1, Nobuo Matsuhashi, Osamu Ichii, Tomohiro Suzuki, Yutaka Ejiri, Satoshi Kono, Tatsuhiro Terada, Hiroaki Miyajima, Masaru Harada.   

Abstract

Aceruloplasminemia is an autosomal recessive disease characterized by an abnormal iron metabolism. The absence of ferroxidase activity caused by mutation of ceruloplasmin leads to iron overload in the brain, liver and other organs. We report a 35-year-old man who was diagnosed with aceruloplasminemia without neurological manifestation despite the accumulation of iron in the brain and liver. To prevent the development of neurodegenerative disorder related to iron toxicity, iron depletion therapy was performed. Iron chelator deferasirox was effective in reducing serum ferritin level and to prevent the progression of the disease.
© 2013 The Japan Society of Hepatology.

Entities:  

Keywords:  aceruloplasminemia; copper; deferasirox; iron

Year:  2014        PMID: 24341521     DOI: 10.1111/hepr.12292

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  8 in total

Review 1.  Aceruloplasminaemia: a rare but important cause of iron overload.

Authors:  Adam Doyle; Ferry Rusli; Prithi Bhathal
Journal:  BMJ Case Rep       Date:  2015-05-14

2.  Is aceruloplasminemia treatable? Combining iron chelation and fresh-frozen plasma treatment.

Authors:  L Poli; A Alberici; P Buzzi; E Marchina; A Lanari; C Arosio; A Ciccone; F Semeraro; R Gasparotti; A Padovani; Barbara Borroni
Journal:  Neurol Sci       Date:  2016-11-05       Impact factor: 3.307

3.  Aceruloplasminemia with Abnormal Compound Heterozygous Mutations Developed Neurological Dysfunction during Phlebotomy Therapy.

Authors:  Maki Watanabe; Ken Ohyama; Masashi Suzuki; Yasunobu Nosaki; Takashi Hara; Katsushige Iwai; Satoshi Kono; Hiroaki Miyajima; Kenji Mokuno
Journal:  Intern Med       Date:  2018-04-27       Impact factor: 1.271

Review 4.  Emerging Disease-Modifying Therapies in Neurodegeneration With Brain Iron Accumulation (NBIA) Disorders.

Authors:  Vassilena Iankova; Ivan Karin; Thomas Klopstock; Susanne A Schneider
Journal:  Front Neurol       Date:  2021-04-15       Impact factor: 4.003

5.  Dementia as a core clinical feature of a patient with aceruloplasminemia.

Authors:  Farzad Ashrafi; Mehri Salari; Fatemeh Nouri; Fatemeh Shiravi
Journal:  Clin Case Rep       Date:  2022-03-13

6.  A New Pathogenic Missense Variant in a Consanguineous North-African Family Responsible for a Highly Variable Aceruloplasminemia Phenotype: A Case-Report.

Authors:  Hervé Lobbes; Quitterie Reynaud; Sabine Mainbourg; Claire Savy-Stortz; Martine Ropert; Edouard Bardou-Jacquet; Stéphane Durupt
Journal:  Front Neurosci       Date:  2022-05-02       Impact factor: 4.677

7.  A novel ceruloplasmin mutation identified in a Chinese patient and clinical spectrum of aceruloplasminemia patients.

Authors:  Wan-Qing Xu; Wang Ni; Rou-Min Wang; Yi Dong; Zhi-Ying Wu
Journal:  Metab Brain Dis       Date:  2021-08-04       Impact factor: 3.584

8.  Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports.

Authors:  Lena H P Vroegindeweij; Agnita J W Boon; J H Paul Wilson; Janneke G Langendonk
Journal:  Orphanet J Rare Dis       Date:  2020-04-25       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.